Amgen
AMGN
$366.29
-1.42%
Amgen is a global leader in biotechnology-based human therapeutics, developing and commercializing innovative drugs across oncology, inflammation, bone health, cardiovascular, and rare diseases. As one of the world's largest independent biotech firms, it distinguishes itself through a deep pipeline of flagship products like Enbrel, Prolia, and Repatha, along with a growing biosimilar portfolio and the recent Horizon acquisition adding rare-disease assets such as Tepezza. The current investor narrative centers on Amgen's ability to sustain growth amid patent expirations, regulatory scrutiny over its Tavneos drug, and the impact of new U.S. drug tariffs, while the market debates the durability of its margin expansion and the potential of recent launches like Lumakras and Tezspire.…
AMGN
Amgen
$366.29
Related headlines
Investment Opinion: Should I buy AMGN Today?
Rating: Hold. Amgen is a high-quality biotech with strong cash flows and a reasonable forward valuation, but near-term upside is limited by regulatory risks and margin headwinds. The consensus analyst rating is Buy with an average target of $356.62, implying a slight 0.5% downside from the current price of $358.32, suggesting the stock is fairly valued at current levels.
Supporting Evidence: Amgen's forward P/E of 15.28x is attractive relative to its trailing P/E of 22.84x and the industry average of ~18x, indicating expected earnings growth. Revenue grew 5.8% YoY to $8.618B in Q1 2026, with operating margin expanding to 30.9% from 14.5% a year earlier. Free cash flow of $8.6B provides a 4.9% yield on enterprise value, supporting the dividend (2.9% yield). The PEG ratio of 0.26 suggests the stock is undervalued relative to its growth rate, but the high debt load (D/E 6.31x) and gross margin compression (down 670bps) temper enthusiasm.
Risks & Conditions: The Hold rating would upgrade to Buy if the Tavneos regulatory risk is resolved favorably (e.g., label update without sales impact) or if the stock pulls back to the $320 level (10% downside), offering a better entry point. It would downgrade to Sell if gross margins fall below 65% or if revenue growth decelerates below 3% YoY. Overall, Amgen appears fairly valued relative to its history and peers, with the forward P/E near the industry average and the trailing P/E below its 5-year average of 25x.
Sign up to view all
AMGN 12-Month Price Forecast
Amgen presents a balanced risk/reward profile over the next 12 months. The base case of steady growth and stable margins is most likely (50% probability), with the stock trading near the analyst average target. The bull case (25%) requires favorable resolution of regulatory and tariff risks, while the bear case (25%) hinges on adverse outcomes. The neutral stance reflects the limited near-term upside to the average target and the presence of significant binary risks. An upgrade to bullish would require clarity on Tavneos and tariffs, while a downgrade to bearish would follow negative regulatory or tariff developments.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Amgen's 12-month outlook, with a consensus price target around $356.62 and implied upside of -2.6% versus the current price.
Average Target
$356.62
0 analysts
Implied Upside
-2.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$215 - $427
Analyst target range
Amgen is covered by 29 analysts, with a consensus recommendation of 'Buy' (mean rating 2.44 on a 1-5 scale where 1 is Strong Buy). The average target price is $356.62, implying a slight 0.5% downside from the current price of $358.32. The distribution shows a bullish lean, with 10 recent ratings including 3 Buys, 6 Neutral/Hold, and 1 Overweight, indicating cautious optimism.
The target price range spans from a low of $215.00 to a high of $427.00, representing a 99% spread between low and high, reflecting high uncertainty. The high target of $427 implies 19% upside and likely assumes successful pipeline execution and margin expansion, while the low target of $215 (-40%) prices in regulatory setbacks (e.g., Tavneos) or competitive pressures. Recent ratings from UBS (Buy), Morgan Stanley (Equal Weight), and Truist (Hold) show a mix of views, with no major upgrades or downgrades in the past month, suggesting a wait-and-see stance.
Drowning in data?
Find the real signal!
Bulls vs Bears: AMGN Investment Factors
Amgen presents a balanced risk/reward profile with strong fundamentals offset by specific risks. On the bull side, the company delivers steady revenue growth (5.8% YoY), high profitability (21.1% net margin), robust free cash flow ($8.6B), and an attractive forward P/E of 15.3x. The low beta (0.40) and analyst consensus Buy provide additional support. However, bears point to a high debt-to-equity ratio (6.31x), gross margin compression (down 670bps YoY), regulatory risks from Tavneos, and drug tariff uncertainty. The single most important tension is whether Amgen can sustain its margin expansion and revenue growth to justify the forward earnings multiple, or if regulatory and competitive pressures will erode profitability. Currently, the bull case has stronger evidence given the consistent financial performance and reasonable valuation, but the Tavneos situation and tariff risks warrant close monitoring.
Bullish
- Strong Revenue Growth Trajectory: Revenue grew 5.8% YoY in Q1 2026 to $8.618B, with sequential acceleration from $8.388B in Q2 2024 to $9.896B in Q4 2025. This steady growth is driven by key products like Prolia ($1.054B), Otezla ($625M), and Horizon-acquired drugs Tepezza ($457M) and Tezspire ($474M), demonstrating a diversified and expanding portfolio.
- High Profitability and Cash Flow: Net margin stands at 21.1% with trailing free cash flow of $8.597B, providing strong cash generation to service debt and fund dividends. Operating margin improved to 30.9% in Q1 2026 from 14.5% a year earlier, reflecting disciplined cost management and operating leverage.
- Attractive Forward Valuation: Forward P/E of 15.28x is well below the trailing P/E of 22.84x, implying the market expects significant earnings growth. This forward multiple is in line with the industry average, while the PEG ratio of 0.26 suggests the stock is undervalued relative to its growth rate.
- Low Volatility Defensive Profile: With a beta of 0.40, Amgen is 60% less volatile than the S&P 500, making it a defensive holding suitable for conservative portfolios. The stock has outperformed the S&P 500 over the past year (22.5% vs. 20.9%), offering both downside protection and upside participation.
Bearish
- High Debt-to-Equity Ratio: Debt-to-equity of 6.31x is extremely high, reflecting significant leverage from the Horizon acquisition. While free cash flow covers interest, this limits financial flexibility and increases vulnerability to rising interest rates or earnings shocks.
- Tavneos Safety and Regulatory Risk: The FDA has warned of fatal liver risks linked to Tavneos, and Amgen's Japanese partner urged caution on its use. This rare-disease drug faces potential sales restrictions or withdrawal, which could impact revenue and create reputational damage.
- Drug Tariff Uncertainty: The Trump administration's proposed 100% tariff on imported drugs could disrupt Amgen's supply chain and cost structure. While Amgen may have exemption deals, the uncertainty creates a risk premium that could weigh on the stock.
- Gross Margin Compression: Gross margin declined from 74.9% in Q1 2025 to 68.2% in Q1 2026, driven by product mix shifts and higher cost of revenue. This trend could persist as newer, lower-margin products (including biosimilars) grow as a percentage of sales.
AMGN Technical Analysis
Amgen is in a sustained uptrend, with the stock up 22.5% over the past year, significantly outperforming the S&P 500's 20.9% gain. The current price of $358.32 sits at 72% of its 52-week range ($269.77–$391.29), indicating it is closer to the highs but not overextended, suggesting positive momentum with room for further upside. The stock's beta of 0.40 implies it is significantly less volatile than the market, making it a defensive holding within the healthcare sector.
Short-term momentum shows a 1-month gain of 2.2% and a 3-month gain of 2.6%, both positive but decelerating relative to the 1-year trend. The 1-month relative strength of 1.62 versus the S&P 500 indicates slight outperformance, but the 3-month relative strength of -3.73 suggests a recent loss of momentum compared to the broader market. This divergence could signal a consolidation phase or a temporary pullback within the longer-term uptrend, rather than a reversal.
The 52-week low of $269.77 provides strong support, while the 52-week high of $391.29 acts as key resistance. A breakout above $391 would signal a resumption of the uptrend, while a breakdown below $270 would indicate a bearish reversal. With a beta of 0.40, Amgen is 60% less volatile than the S&P 500, making it a lower-risk holding suitable for conservative portfolios, though its low volatility may limit upside during strong market rallies.
Beta
0.40
0.40x market volatility
Max Drawdown
-16.6%
Largest decline past year
52-Week Range
$270-$391
Price range past year
Annual Return
+22.8%
Cumulative gain past year
| Period | AMGN Return | S&P 500 |
|---|---|---|
| 1m | +7.2% | +0.3% |
| 3m | +3.1% | +4.7% |
| 6m | +10.9% | +7.5% |
| 1y | +22.8% | +18.4% |
| ytd | +11.8% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AMGN Fundamental Analysis
Amgen's revenue trajectory is growing, with Q1 2026 revenue of $8.618 billion, up 5.8% year-over-year from $8.149 billion in Q1 2025. The multi-quarter trend shows revenue increasing from $8.388 billion in Q2 2024 to $8.503 billion in Q3 2024, $9.086 billion in Q4 2024, $9.167 billion in Q2 2025, $9.556 billion in Q3 2025, and $9.896 billion in Q4 2025, indicating steady acceleration. Key growth drivers include Prolia ($1.054B), Otezla ($625M), and EVENITY ($599M), while the Horizon acquisition added TEPEZZA ($457M) and TEZSPIRE ($474M). The growth trajectory supports the investment case for a mature biotech with a diversified portfolio.
Amgen is highly profitable, with Q1 2026 net income of $1.819 billion and a net margin of 21.1%. Gross margin was 68.2% in Q1 2026, down from 74.9% in Q1 2025, reflecting product mix shifts and higher cost of revenue. Operating margin improved to 30.9% in Q1 2026 from 14.5% in Q1 2025, driven by disciplined expense management. The trailing twelve-month free cash flow of $8.597 billion underscores strong cash generation, though net income has fluctuated due to acquisition-related costs and interest expenses.
Amgen's balance sheet shows a debt-to-equity ratio of 6.31, indicating significant leverage, but the company generates robust free cash flow ($1.477 billion in Q1 2026) to service debt. The current ratio of 1.14 suggests adequate liquidity, while ROE of 89.1% is exceptionally high, driven by leverage and strong profitability. Free cash flow yield (FCF/EV) is approximately 4.9%, providing a cushion for debt repayment and dividends. The high debt load is manageable given the consistent cash flow, but it limits financial flexibility.
Quarterly Revenue
$8.6B
2026-03
Revenue YoY Growth
+5.8%
YoY Comparison
Gross Margin
68.2%
Latest Quarter
Free Cash Flow
$8.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AMGN Overvalued?
Since net income is positive ($1.819 billion), we lead with the P/E ratio. The trailing P/E is 22.84x, while the forward P/E is 15.28x, implying the market expects significant earnings growth. The gap between trailing and forward P/E suggests that the market is pricing in a 33% earnings increase over the next year, which aligns with analyst estimates for EPS growth.
Compared to the industry average (Drug Manufacturers - General), Amgen's trailing P/E of 22.84x is at a premium to the sector median of approximately 18x (based on industry data), representing a 27% premium. This premium is justified by Amgen's superior net margin of 21.1% versus the industry average of around 15%, and its strong free cash flow generation. However, the forward P/E of 15.28x is more in line with the sector, suggesting the premium may narrow as growth materializes.
Historically, Amgen's trailing P/E has ranged from 11.4x (Q1 2023) to 75.2x (Q2 2021), with the current 22.84x near the middle of its 5-year band. The current P/E is below the 5-year average of approximately 25x, indicating the stock is not overvalued relative to its own history. This suggests that the market is pricing in reasonable expectations, with room for multiple expansion if growth accelerates.
PE
22.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 11x~33x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Amgen's debt-to-equity ratio of 6.31x is among the highest in the biotech sector, reflecting the $28 billion Horizon acquisition. While the company generates $8.6 billion in trailing free cash flow, interest expense of $657 million in Q1 2026 consumes a significant portion of operating income. Gross margin compression from 74.9% to 68.2% over the past year signals product mix deterioration, as newer drugs like Tezspire and biosimilars carry lower margins. Net income has been volatile, swinging from $1.8B in Q1 2026 to $1.3B in Q4 2025, partly due to acquisition-related costs. The high payout ratio of 66.5% leaves limited room for dividend growth if earnings falter.
Market & Competitive Risks: Amgen's trailing P/E of 22.84x is at a 27% premium to the industry median of ~18x, making it vulnerable to multiple compression if growth disappoints. The stock's beta of 0.40 provides downside protection but also limits upside in strong market rallies, as evidenced by relative strength of -3.73% over the past 3 months vs. the S&P 500. Regulatory risks are elevated: the FDA's warning on Tavneos (fatal liver injury) could lead to label restrictions or withdrawal, while the proposed 100% drug tariffs create cost uncertainty. Competition in key markets is intensifying, with Eli Lilly and Novo Nordisk dominating the weight-loss space and biosimilar competition eroding Enbrel sales.
Worst-Case Scenario: A confluence of adverse events—Tavneos withdrawal, imposition of 100% tariffs without exemption, and a recession compressing growth stock multiples—could drive Amgen's stock to its 52-week low of $269.77, representing a 24.7% decline from the current price of $358.32. In a more severe scenario, the analyst low target of $215 implies a 40% loss. Historical max drawdown of -16.57% suggests that even in normal downturns, the stock is not immune to significant corrections. An investor could lose up to 40% ($143 per share) in the most adverse scenario.
FAQ
The primary risks are: (1) Regulatory risk from Tavneos, where the FDA has warned of fatal liver injuries, potentially leading to sales restrictions or withdrawal. (2) Financial risk from high leverage, with a debt-to-equity ratio of 6.31x, making the company vulnerable to rising interest rates or earnings shocks. (3) Macro risk from proposed 100% drug tariffs, which could increase costs and disrupt supply chains. (4) Competitive risk from biosimilar erosion of key products like Enbrel and from rivals in high-growth areas like weight-loss drugs. The most severe risk is a Tavneos-related event, which could trigger a 24.7% decline to the 52-week low of $269.77.
The 12-month outlook is balanced with three scenarios. The base case (50% probability) sees the stock trading between $340 and $380, near the analyst average target of $356.62, assuming steady growth and stable margins. The bull case (25% probability) targets $380-$427, driven by favorable resolution of Tavneos and tariff risks and strong earnings. The bear case (25% probability) sees a decline to $270-$340, potentially as low as $215, if Tavneos is withdrawn or tariffs are imposed. The most likely scenario is the base case, where Amgen continues its mid-single-digit growth trajectory and the stock remains range-bound.
Amgen appears fairly valued based on current metrics. The trailing P/E of 22.84x is at a 27% premium to the industry median of ~18x, but this is justified by superior net margins (21.1% vs. industry ~15%) and strong free cash flow. The forward P/E of 15.28x is in line with the industry, implying the market expects earnings growth to close the gap. Historically, the trailing P/E is below the 5-year average of 25x, suggesting the stock is not overvalued relative to its own history. The PEG ratio of 0.26 indicates undervaluation relative to growth, but the high debt-to-equity of 6.31x tempers this. Overall, the market is pricing in reasonable expectations, and the stock is neither clearly overvalued nor undervalued.
Amgen is a reasonable buy for conservative investors seeking a defensive biotech with steady growth and income. The stock offers a forward P/E of 15.28x, a 2.9% dividend yield, and low beta of 0.40, providing downside protection. However, the average analyst target of $356.62 implies only 0.5% downside from the current price of $358.32, suggesting limited near-term upside. The biggest downside risk is a 24.7% decline to the 52-week low of $269.77 if Tavneos or tariff issues materialize. For long-term investors with a 3-5 year horizon, the attractive PEG ratio of 0.26 and strong free cash flow make it a compelling hold, but traders may find better opportunities elsewhere given the low volatility and limited upside.
Amgen is better suited for long-term investment due to its low beta (0.40), steady dividend (2.9% yield), and strong free cash flow generation. The stock's low volatility makes it less attractive for short-term trading, as it tends to move slowly and offers limited upside catalysts in the near term. The defensive profile and reasonable valuation (forward P/E 15.28x) make it a core holding for conservative portfolios with a minimum holding period of 3-5 years. Short-term traders may find the stock unexciting given its 1-month relative strength of 1.62 vs. the S&P 500 and limited price momentum. The high debt load and regulatory risks add uncertainty that is better absorbed over a longer horizon.
